Candel reports CAN-2409 phase 2 interim data: median OS 28.8 vs 12.5 months in pancreatic cancer

Candel Therapeutics, Inc.

Estimated median overall survival 28.8 months for CAN-2409 group vs 12.5 months for control in borderline resectable PDAC.
24-month survival rate 71.4% for CAN-2409 vs 16.7% control; 36-month rate 47.6% vs 16.7%.
4 of 7 CAN-2409 patients alive at data cut-off (2 >50 months); only 1 of 6 control alive.
Immune activation confirmed: dense CD8+ TILs, dendritic cells, B cells in tumor; increased granzymes and IFN-γ in blood.
No dose-limiting toxicities or pancreatitis; FDA Fast Track Designation granted in December 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.